<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205556</url>
  </required_header>
  <id_info>
    <org_study_id>METC VUmc 03/097</org_study_id>
    <secondary_id>ISRCTN38365125</secondary_id>
    <secondary_id>CCMO number P03.1089L</secondary_id>
    <secondary_id>Dutch Kidney Found C 02.2019</secondary_id>
    <nct_id>NCT00205556</nct_id>
  </id_info>
  <brief_title>Effect of Increased Convective Clearance by On-Line Hemodiafiltration on All Cause Mortality in Chronic Hemodialysis Patients</brief_title>
  <acronym>CONTRAST</acronym>
  <official_title>Effect of Increased Convective Clearance by On-line Hemodiafiltration on All Cause and Cardiovascular Mortality in Chronic Hemodialysis Patients: The Dutch Convective Transport Study (CONTRAST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Julius Center for Health Sciences and Primary Care, Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gambro Renal Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of low flux hemodialysis with online
      hemodiafiltration on all cause mortality and a combination of cardiovascular morbidity and
      mortality in chronic hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Today, an increasing number of patients with chronic renal failure (CRF) is treated with
      (on-line) hemodiafiltration (HDF). This practice is based on the assumption that the high
      incidence of cardiovascular (CV) disease, as observed in patients with CRF, is at least
      partially related to the retention of uremic toxins in the middle and large-middle molecular
      (MM) range. As HDF lowers these molecules more effectively than HD, it has been suggested
      that this treatment improves CV outcome, if compared to standard HD.

      Thus far, no definite data on the effects of HDF on CV parameters and/or clinical end-points
      are available. Promising data include a reduction of left ventricular mass index (LVMi) after
      one year of treatment with acetate free bio-filtration (AFB). Furthermore, relatively high
      survival rates were reported in a single center non-experimental study on patients who were
      treated with HDF, if compared to the EDTA registry data on HD-treated patients. Yet, these
      data are of observational nature, with the possibility of being biased by confounding by
      indication.

      As the accumulation of MMW substances has been implicated in increased oxidative stress and
      endothelial dysfunction, a reduction of these compounds might improve these derangements. In
      addition, cardiac dysfunction, atherosclerosis (as measured by left ventricular mass index
      [LVMi], carotid intima media thickness [CIMT]) and vascular stiffness (as measured by pulse
      wave velocity [PWV]) might be reduced during HDF, as compared to low-flux HD.

      Therefore, we propose a prospective, randomized multicenter trial, comparing (on-line) HDF
      with HD. After a stabilization period, an expected number of 700 chronic HD patients will be
      randomized to either HDF or low-flux HD and followed during 1-6 years. Primary end points are
      all cause mortality and combined CV events and mortality. In addition, LVMi, PWV, CIMT and
      various parameters of oxidative stress, acute phase reaction (APR) and endothelial function
      will be assessed and compared between treatment groups.

      This study will provide strong evidence on the efficacy of HDF compared to low flux HD on CV
      morbidity and mortality, which is currently lacking but urgently needed. It is highly likely
      that the outcome of this study will affect current clinical practice considerably, in the
      Netherlands as well as internationally. Moreover, the study will point towards the mechanisms
      underlying the effects of HDF.

      The following hypotheses will be tested:

        1. All-cause mortality and combined CV morbidity and mortality in patients treated with
           (on-line) HDF is lower than in patients treated with standard low-flux HD.

        2. A reduction in MMW uremic toxins by HDF leads to an improvement of the 'uremic profile'
           (as measured by AGE-levels, homocysteine levels, oxidative stress, and endothelial
           dysfunction), if compared to standard low-flux HD.

        3. The improvement of the 'uremic profile' in HDF-treated patients results in an
           improvement of endothelial function with a reduction in the progression of vascular
           injury (as measured by CIMT and PWV) and a reduction in LVMi, if compared to standard
           low-flux HD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>entire follow up (until dead or end of study, 1-7 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fatal and non-fatal cardiovascular events</measure>
    <time_frame>entire follow up (until death or end of study, 1-7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass index (LVMi), carotid IMT (intima media thickness), aortic pulse wave velocity (PWV)</measure>
    <time_frame>first 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory markers of endothelial dysfunction, micro-inflammation, oxidative stress</measure>
    <time_frame>first three years of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profiles, uremic toxins</measure>
    <time_frame>first three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>entire follow up (until death or end of study, 1-7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutritional state</measure>
    <time_frame>entire follow up (until death or end of study 1-7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anemia management</measure>
    <time_frame>first 12 months of follow up</time_frame>
    <description>hemoglobin levels, erythropoietin use / resistance iron saturation / ferritin levels, prescription of iron medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost utility analysis</measure>
    <time_frame>entire follow up (until death or end of study, 1-7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital admissions</measure>
    <time_frame>entire follow up (until death or end of study, 1-7 years)</time_frame>
    <description>hospitalization days hospital admission for infections hospital admission for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure and antihypertensive medication</measure>
    <time_frame>entire follow up (until death or end of study, 1-7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>residual kidney function</measure>
    <time_frame>entire follow up (until death or end of study, 1-7 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mineral bone disease</measure>
    <time_frame>entire follow up (until death or end of study, 1-7 years)</time_frame>
    <description>laboratory parameters of mineral bone disease and medication (phosphate binders, vitamin D (or analogues), cinacalet)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parameters of treatment / treatment delivery</measure>
    <time_frame>entire follow up (until death or end of study, 1-7 years)</time_frame>
    <description>dialysis efficiency (Kt/V urea); bloodflow, dialysate flow, ultrafiltration volume, (HDF:) convection volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">715</enrollment>
  <condition>End-stage Renal Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1: low flux hemodialysis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 on-line hemodiafiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>on-line hemodiafiltration</intervention_name>
    <description>addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration</description>
    <arm_group_label>2 on-line hemodiafiltration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>low flux hemodialysis</intervention_name>
    <description>standard treatment</description>
    <arm_group_label>1: low flux hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated by HD 2 or 3 times a week, for at least 2 months

          -  Patients able to understand the study procedures

          -  Patients willing to provide written informed consent

        Exclusion Criteria:

          -  Current age &lt; 18 years

          -  Treatment by HDF or high flux HD in the preceding 6 months

          -  Severe incompliance (severe non-adherence to the dialysis procedure and accompanying
             prescriptions, especially frequency and duration of dialysis treatment and fluid
             restriction)

          -  Life expectancy &lt; 3 months due to non renal disease

          -  Participation in other clinical intervention trials evaluating cardiovascular outcome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Menso J Nubé, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Center Alkmaar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piet M ter Wee, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vrije Universiteit Medical Center, Amsterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter J Blankestijn, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universityr Medical Center Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>René A van den Dorpel, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medisch Centrum Rijnmond Zuid - locatie Clara, Rotterdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michiel L Bots, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Julius Center for Health Sciences and Primary Care, Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muriel PC Grooteman, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vrije Universiteit Medical Center, Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Georges-L. Dumont Regional Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de L'Université de Montreal, Hopital Notre Dame</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s Hertogenbosch</city>
        <zip>5200 ME</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academical Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse Kliniek Noord</name>
      <address>
        <city>Beilen</city>
        <zip>9411 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis (locatie Leyenburg)</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slingeland Ziekenhuis</name>
      <address>
        <city>Doetinchem</city>
        <zip>7009 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <zip>6710 HN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oosterscheldeziekenhuis</name>
      <address>
        <city>Goes</city>
        <zip>4460 BB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnland Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscus Ziekenhuis</name>
      <address>
        <city>Roosendaal</city>
        <zip>4700 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Rijnmond Zuid - locatie Clara</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbis Medisch en Zorgcentrum</name>
      <address>
        <city>Sittard</city>
        <zip>6130 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Zeeuws-Vlaanderen</name>
      <address>
        <city>Terneuzen</city>
        <zip>4535 PA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5000 LC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stichting Dianet</name>
      <address>
        <city>Utrecht</city>
        <zip>3524 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8000 GM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nubé MJ, van der Tweel I, Ter Wee PM; the CONTRAST study group. Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]. Curr Control Trials Cardiovasc Med. 2005 May 20;6(1):8.</citation>
    <PMID>15907201</PMID>
  </reference>
  <reference>
    <citation>Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nubé MJ, ter Wee PM; CONTRAST Group. Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study. Semin Dial. 2005 Jan-Feb;18(1):47-51. Review.</citation>
    <PMID>15663765</PMID>
  </reference>
  <reference>
    <citation>Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nubé MJ, ter Wee PM. [New study evaluating online haemodiafiltration for the reduction of cardiovascular morbidity and mortality in patients undergoing chronic haemodialysis]. Ned Tijdschr Geneeskd. 2006 Jul 15;150(28):1583-5. Dutch.</citation>
    <PMID>16886698</PMID>
  </reference>
  <reference>
    <citation>van der Weerd NC, Penne EL, van den Dorpel MA, Grooteman MP, Nube MJ, Bots ML, ter Wee PM, Blankestijn PJ. Haemodiafiltration: promise for the future? Nephrol Dial Transplant. 2008 Feb;23(2):438-43. Epub 2007 Nov 28. Review.</citation>
    <PMID>18045819</PMID>
  </reference>
  <reference>
    <citation>Penne EL, van Berkel T, van der Weerd NC, Grooteman MP, Blankestijn PJ. Optimizing haemodiafiltration: tools, strategy and remaining questions. Nephrol Dial Transplant. 2009 Dec;24(12):3579-81. doi: 10.1093/ndt/gfp333. Epub 2009 Jul 13.</citation>
    <PMID>19596741</PMID>
  </reference>
  <reference>
    <citation>van der Weerd NC, Penne EL, Grooteman MP. Effect of hemofiltration on mortality: no definite answer yet. Am J Kidney Dis. 2009 Mar;53(3):562-3; author reply 563. doi: 10.1053/j.ajkd.2008.09.029.</citation>
    <PMID>19231743</PMID>
  </reference>
  <reference>
    <citation>Penne EL, Visser L, van den Dorpel MA, van der Weerd NC, Mazairac AH, van Jaarsveld BC, Koopman MG, Vos P, Feith GW, Kremer Hovinga TK, van Hamersvelt HW, Wauters IM, Bots ML, Nubé MJ, Ter Wee PM, Blankestijn PJ, Grooteman MP. Microbiological quality and quality control of purified water and ultrapure dialysis fluids for online hemodiafiltration in routine clinical practice. Kidney Int. 2009 Sep;76(6):665-72. doi: 10.1038/ki.2009.245. Epub 2009 Jul 15.</citation>
    <PMID>19606080</PMID>
  </reference>
  <reference>
    <citation>den Hoedt CH, Mazairac AH, van den Dorpel MA, Grooteman MP, Blankestijn PJ. Effect of hemodiafiltration on mortality, inflammation and quality of life. Contrib Nephrol. 2011;168:39-52. doi: 10.1159/000321743. Epub 2010 Oct 7. Review.</citation>
    <PMID>20938124</PMID>
  </reference>
  <results_reference>
    <citation>Penne EL, van der Weerd NC, Bots ML, van den Dorpel MA, Grooteman MP, Lévesque R, Nubé MJ, Ter Wee PM, Blankestijn PJ; CONTRAST investigators. Patient- and treatment-related determinants of convective volume in post-dilution haemodiafiltration in clinical practice. Nephrol Dial Transplant. 2009 Nov;24(11):3493-9. doi: 10.1093/ndt/gfp265. Epub 2009 Jun 10.</citation>
    <PMID>19515802</PMID>
  </results_reference>
  <results_reference>
    <citation>Penne EL, van der Weerd NC, van den Dorpel MA, Grooteman MP, Lévesque R, Nubé MJ, Bots ML, Blankestijn PJ, ter Wee PM; CONTRAST Investigators. Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis. 2010 Jan;55(1):77-87. doi: 10.1053/j.ajkd.2009.09.023. Epub 2009 Dec 5.</citation>
    <PMID>19962805</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazairac AH, de Wit GA, Penne EL, van der Weerd NC, Grooteman MP, van den Dorpel MA, Nubé MJ, Buskens E, Lévesque R, Ter Wee PM, Bots ML, Blankestijn PJ; CONTRAST investigators. Protein-energy nutritional status and kidney disease-specific quality of life in hemodialysis patients. J Ren Nutr. 2011 Sep;21(5):376-386.e1. doi: 10.1053/j.jrn.2010.08.004. Epub 2010 Dec 30.</citation>
    <PMID>21194971</PMID>
  </results_reference>
  <results_reference>
    <citation>Penne EL, van der Weerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, Nubé MJ, Bots ML, Lévesque R, ter Wee PM, Blankestijn PJ; CONTRAST investigators. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2011 Feb;6(2):281-9. doi: 10.2215/CJN.04480510. Epub 2010 Oct 28.</citation>
    <PMID>21030579</PMID>
  </results_reference>
  <results_reference>
    <citation>Penne EL, van der Weerd NC, Blankestijn PJ, van den Dorpel MA, Grooteman MP, Nubé MJ, Ter Wee PM, Lévesque R, Bots ML; CONTRAST investigators. Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol. 2010 Jan;5(1):80-6. doi: 10.2215/CJN.03340509. Epub 2009 Nov 12.</citation>
    <PMID>19965537</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazairac AH, de Wit GA, Grooteman MP, Penne EL, van der Weerd NC, van den Dorpel MA, Nubé MJ, Lévesque R, Ter Wee PM, Bots ML, Blankestijn PJ; CONTRAST investigators. A composite score of protein-energy nutritional status predicts mortality in haemodialysis patients no better than its individual components. Nephrol Dial Transplant. 2011 Jun;26(6):1962-7. doi: 10.1093/ndt/gfq643. Epub 2010 Oct 14.</citation>
    <PMID>20947533</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazairac AH, de Wit GA, Penne EL, van der Weerd NC, de Jong B, Grooteman MP, van den Dorpel MA, Buskens E, Dekker FW, Nubé MJ, Ter Wee PM, Boeschoten EW, Bots ML, Blankestijn PJ; CONTRAST investigators. Changes in quality of life over time--Dutch haemodialysis patients and general population compared. Nephrol Dial Transplant. 2011 Jun;26(6):1984-9. doi: 10.1093/ndt/gfq680. Epub 2010 Nov 4.</citation>
    <PMID>21051503</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 20, 2011</last_update_submitted>
  <last_update_submitted_qc>January 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>contact person: MPC Grooteman MD PhD</name_title>
    <organization>Vrije Universiteit Medical Center and University Medical Center Utrecht</organization>
  </responsible_party>
  <keyword>online hemodiafiltration</keyword>
  <keyword>low flux hemodialysis</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>uremic toxicity</keyword>
  <keyword>quality of life</keyword>
  <keyword>nutritional status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 1, 2017</submitted>
    <returned>April 12, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

